Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Receivables (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed Receivables for 11 consecutive years, with $89.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Receivables rose 13.63% year-over-year to $89.9 million, compared with a TTM value of $89.9 million through Dec 2025, up 13.63%, and an annual FY2025 reading of $89.9 million, up 13.63% over the prior year.
  • Receivables was $89.9 million for Q4 2025 at Heron Therapeutics, up from $81.0 million in the prior quarter.
  • Across five years, Receivables topped out at $89.9 million in Q4 2025 and bottomed at $35.7 million in Q4 2021.
  • Average Receivables over 5 years is $60.4 million, with a median of $62.0 million recorded in 2023.
  • The sharpest move saw Receivables decreased 15.27% in 2021, then surged 90.29% in 2023.
  • Year by year, Receivables stood at $35.7 million in 2021, then soared by 62.95% to $58.2 million in 2022, then rose by 3.28% to $60.2 million in 2023, then soared by 31.56% to $79.1 million in 2024, then rose by 13.63% to $89.9 million in 2025.
  • Business Quant data shows Receivables for HRTX at $89.9 million in Q4 2025, $81.0 million in Q3 2025, and $79.9 million in Q2 2025.